Innate Pharma reports €2.3 million revenue for first nine months of 2025
Innate Pharma SA reported €2.3 million in revenue for the first nine months of 2025, down from €10.2 million in the same period of 2024. As of September 30, 2025, the company had €56.4 million in cash and financial assets, with financial liabilities of €24.8 million. Key developments included FDA clearance for the TELLOMAK-3 study and progress in various clinical trials, including collaborations with AstraZeneca and Sanofi.
Innate Pharma SA reported cash, cash equivalents, and financial assets totaling €56.4 million as of September 30, 2025, with financial liabilities of €24.8 million. Revenues for the first nine months of 2025 were €2.3 million, compared to €10.2 million for the same period in 2024. Revenue from collaboration and licensing agreements mainly resulted from agreements with AstraZeneca and Sanofi. Key business developments included FDA clearance to initiate the TELLOMAK-3 study for lacutamab, advancement toward a Phase 3 trial in Sézary syndrome, ongoing dose-escalation studies for IPH4502 with data expected in the first half of 2026, and continued recruitment for the IPH5201 Phase 2 trial in collaboration with AstraZeneca. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112563057) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
